$2.370
+0.072 (+3.04%)收盘时
MENS 资讯
MENS 事件
Jyong Biotech Updates MCS-8 Clinical Trial Data
Jyong Biotech announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 conducted in Taiwan. The results underscore MCS-8's previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in prostate cancer prevention, showing its potential in helping alleviate high-grade malignancy risk. The data reveals significant new value in metabolic indicators, specifically cholesterol and lactate dehydrogenase. Building on this momentum, the Company is evaluating the feasibility of expanding MCS-8's indications to include lipid management, atherosclerosis, and cardiovascular diseases-a strategic move aimed at extending the product's lifecycle and significantly capturing a broader market share. The Phase II clinical trial demonstrated that after two years of treatment, subjects receiving MCS-8 showed improved lipid control compared with baseline, including: A statistically significant reduction in total cholesterol levels; A statistically significant increase in serum lactate dehydrogenase levels observed in the placebo group, while no such increase was observed in the MCS-8 group.
Jyong Biotech Notes Share Price Fluctuation and Increased Trading Volume
Jyong Biotech noted the recent fluctuation in its share price and the increased trading volume of its shares on the Nasdaq Stock Exchange following the expiry of the lock-up period this month. The company said, "The Company has been in ongoing discussions with certain investment funds that are interested in purchasing the Company's ordinary shares. The Company confirms that it is in compliance with its continuous disclosure obligations under the SEC regulations. The Company is not aware of any material, unpublished price-sensitive information or corporate developments that would explain the recent trading activity. The Company's research and development, operation remain solid and its financial condition and results of operations remain consistent with the information disclosed in its most recent public filings, including but not limited to its Current Report on Form 6-K. Jyong Biotech cautions its investors that share price movements can be influenced by various factors, including general market conditions, sector-specific news, and general supply and demand dynamics, which are beyond the Company's control. The Company remains committed to keeping its shareholders informed of all material developments in accordance with applicable laws and regulations."
Jyong Biotech Ltd Trading Halted Due to Volatility Trading Pause
Jyong Biotech Ltd trading halted, volatility trading pause
Jyong Biotech Signs MOU with Vietnam Pharma Company
Jyong Biotech announced that it has entered into a non-binding Memorandum of Understanding, MOU, with a Vietnam-based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialization of MCS-2 in the Vietnam pharmaceutical market. Under the terms of the MOU, Jyong Biotech and the Vietnam pharmaceutical distribution company will proceed with due diligence and discussions to determine the scope and structure of any definitive collaboration, including commercial strategy, regulatory pathway and local market execution. There can be no assurance that any definitive agreement will be reached or that any contemplated collaboration will be consummated.
Jyong Biotech Enters Non-Binding Letter of Intent with South Korean Pharmaceutical Firm
Jyong Biotech entered into a non-binding letter of intent with a South Korean pharmaceutical company to review and evaluate the potential in-licensing and development of Jyong Biotech's plant-derived new drug MCS-2for the Korean market. The prospective partner is a recognized supplier to both general hospitals and clinics, and the LOI reflects mutual interest in assessing commercial and regulatory pathways for introducing MCS products in Korea. This engagement is consistent with Jyong Biotech's co-commercialization strategy to collaborate with regional partners that offer established sales networks and local regulatory expertise. Definitive terms are being negotiated between the parties and the partnership, if such definitive terms will be agreed upon, would aim to leverage the partner's commercial infrastructure to accelerate market access and patient reach in Korea. The LOI is non-exclusive and subject to customary due diligence, regulatory review, negotiation of definitive agreements, and other closing conditions.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。